“
TL;DR
It concludes that preclinical results are promising but highlights the failure of many antioxidant drugs beyond phase II clinical trials and the need for large-scale trials.
Antioxidants · 4 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It concludes that preclinical results are promising but highlights the failure of many antioxidant drugs beyond phase II clinical trials and the need for large-scale trials.
Idebenone is noted as a clinical translation success, having been licensed for LHON. However, the review reports that many potential antioxidant drugs have failed to progress beyond phase II in clinical trials, citing low bioavailability, limited tissue targeting, poor antioxidant capacity, and potential toxicity at high doses. The authors note that the field of antioxidative research has garnered increasing interest, with numerous studies demonstrating promising preclinical results. Limitations include the reliance on preclinical data and the difficulty of translating these findings to human therapies. The authors advocate for large-scale clinical trials, improved drug delivery systems, and adaptive clinical trial designs to bridge the gap between preclinical promise and clinical application.